Evidence map›Paper›PMID 29480505›Full record

ArticleJournal of neuro-oncology2018

Salvage therapy outcomes for atypical meningioma.

William C Chen, Jared Hara, Stephen T Magill, Ashley Wu, Manish K Aghi, Philip V Theodosopoulos, Arie Perry, Michael W McDermott, Penny K Sneed, David R Raleigh and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Rational Radionuclide Therapy for Recurrent Meningioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Radiotherapy and radiosurgery for meningiomas.Neuro-oncology advances · 2023
    Article
  15. Review
  16. Radiotherapy for meningiomas.Journal of neuro-oncology · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

William C ChenDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Jared HaraDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Stephen T MagillDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Ashley WuDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Manish K AghiDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Philip V TheodosopoulosDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Arie PerryDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Michael W McDermottDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA.
Penny K SneedDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
David R RaleighDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
Steve E BraunsteinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA. steve.braunstein@ucsf.edu.ORCID http://orcid.org/0000-0002-9841-9357
University of California, San Francisco · US

Funding

National Institutes of Health 1F32CA213944-01
6 · The paper itself

Abstract

Atypical menginomas demonstrate increased clinical aggressiveness characterized by recurrence and diminished survival. The optimal management of atypical meningioma in the recurrent setting is especially not well defined. To characterize outcomes following salvage treatment of recurrent atypical meningioma and to identify risk factors for further recurrence. Retrospective chart review was performed on 65 patients who underwent salvage treatment of atypical meningioma at a single institution. Data were analyzed using the Kaplan-Meier method and Cox proportional hazards modeling. Sixty-five patients with recurrent atypical meningioma and median imaging follow-up of 4.0 years (range 1.9-6.6 years) underwent 62 surgeries and 114 radiation treatments (RT) for salvage therapy. Salvage modality was surgery (21%), surgery/RT (25%), or RT alone (54%), associated with 2 year local freedom from recurrence (LFFR) of 36, 59, and 73%, respectively (P = 0.01). Twenty percent of patients experienced CTCAE grade ≥ 3 toxicity with salvage therapy. Thirty-nine percent of patients experienced ≥ 3 recurrences. The median disease-free survival intervals after first and second salvage treatments were 2.9 and 1.3 years, respectively. On univariate Cox analysis, prior subtotal resection, prior RT, tumor diameter > 2.5 cm, and multifocal local recurrence were associated with recurrence after salvage therapy. On multivariate logistic regression, only multifocal local recurrence was associated with further recurrence. Recurrent atypical meningioma is clinically and pathologically more aggressive than primary atypical meningioma, and the likelihood of durable local control with salvage therapy is lower. Future efforts should identify patients at risk of recurrence, and aggressive upfront treatment should be employed.

Indexed as

Salvage TherapyAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMeningeal NeoplasmsMeningiomaMiddle AgedNeoplasm Recurrence, LocalRadiosurgeryRetrospective StudiesSurvival AnalysisTreatment OutcomeAtypical meningiomaMeningiomaRadiationRadiotherapySalvageStereotactic radiosurgery

Identifiers

PMID29480505
OpenAlexW2791511269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.